EPV 002
Alternative Names: EPV-002Latest Information Update: 09 Oct 2024
Price :
$50 *
At a glance
- Originator University of Pennsylvania
- Developer EpiVario
- Class Drug withdrawal therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Substance-related disorders
Most Recent Events
- 01 Oct 2024 EpiVario receives SBIR grant from the National Institute on Drug Abuse (NIDA) for EPV 002 development for opioid use disorder (OUD)
- 21 Sep 2022 Preclinical trials in Substance-related disorders in USA (unspecified route) (EpiVario pipeline, September 2022)
- 05 Jan 2021 EpiVario entered into an option Agreement with University of Pennsylvania for an epigenetic marker for Alzheimer’s Disease